S&P ASX All Technology

US Dollar vs AUD

Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Get Started

OSTX OS Therapies Incorporated

4.1799

0.1799 (4.50%)

07 Sep 2024 - Closed

Delayed by 15 minutes

Form 3 - Initial statement of beneficial ownership of securities

OS Therapies (AMEX:OSTX)
Historical Stock Chart
From Aug 2024 to Sep 2024

Click Here for more OS Therapies Charts.

OS Therapies (AMEX:OSTX)
Historical Stock Chart
From Sep 2023 to Sep 2024

Click Here for more OS Therapies Charts.

OS Therapies Incorporated News

OS Therapies to Present at H.C. Wainright 26th Annual Global Investment Conference
Thursday 5 September 2024 (3 days ago) • Business Wire

OS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Receives Last Treatment Dose
Thursday 29 August 2024 (1 week ago) • Business Wire

OS Therapies Appoints Borys Shor, PhD to ADC Advisory Board
Thursday 22 August 2024 (2 weeks ago) • Business Wire

OS Therapies Clarifies CUSIP of Common Stock
Thursday 22 August 2024 (3 weeks ago) • Business Wire

OS Therapies Accepted Into Johnson & Johnson Innovation - JLABS
Monday 19 August 2024 (3 weeks ago) • Business Wire

OS Therapies Forms Osteosarcoma Patient Advocacy Advisory Board
Friday 2 August 2024 (1 month ago) • Business Wire

Form 3 - Initial statement of beneficial ownership of securities
Thursday 1 August 2024 (1 month ago) • Edgar (US Regulatory)

OS Therapies Announces Pricing of its Initial Public Offering on NYSE American - Company to Trade under Symbol “OSTX”
Thursday 1 August 2024 (1 month ago) • Business Wire

Form 8-A12B - Registration of securities [Section 12(b)]
Wednesday 31 July 2024 (1 month ago) • Edgar (US Regulatory)

OS Therapies Announces Positive Safety Data from Phase 1 Clinical Trial of OST-HER2 in HER2-Expressing Breast Cancer and in Preclinical Efficacy in Models of Breast Cancer
Thursday 25 July 2024 (2 months ago) • Business Wire

OS Therapies Announces Positive Clinical Update from Ongoing Phase 2b Clinical Trial in Resected, Recurrent Osteosarcoma
Tuesday 4 June 2024 (3 months ago) • Business Wire

More OS Therapies Incorporated News Articles

Verizon Communications

Newcrest Mining

S&P ASX 300 Metals and M...

Sterling vs AUD

Invesco QQQ Trust Series 1

AUD vs US Dollar

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions